Screener
BridgeBio Pharma BBIO Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Cash and cash equivalents | $879,891 | $570,119 |
| Marketable securities | 60,295 | 17,363 |
| Accounts receivable, net | 205,226 | 139,444 |
| Inventories | 32,980 | 26,753 |
| Prepaid expenses and other current assets | 62,914 | 44,070 |
| Total current assets | 1,241,306 | 797,749 |
| Equity method investments | 61,529 | 79,972 |
| Property and equipment, net | 4,941 | 5,366 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's inventories?
- BridgeBio Pharma (BBIO) reported inventories of $32.98M in Q1 2026.
- How has BridgeBio Pharma's inventories changed year-over-year?
- BridgeBio Pharma's inventories increased by 734.1% year-over-year, from $3.95M to $32.98M.
- What does inventories mean?
- Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.
Ask your AI about BridgeBio Pharma's inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude